Trial Profile
Targeting Microenvironment and Cellular Immunity in Sarcomas Weekly trabectedin combined with Metronomic Cyclophosphamide in Patients with Advanced Pretreated Soft-tissue Sarcomas. A Phase I/II study from the French Sarcoma Group.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 13 Dec 2023
Price :
$35
*
At a glance
- Drugs Trabectedin (Primary) ; Cyclophosphamide
- Indications Leiomyosarcoma; Liposarcoma; Soft tissue sarcoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms TARMIC
- 24 Oct 2023 Results of the phase II part of the first study (n=30) assessing the trabectedin in combination with metronomic chemotherapy on the tumor microenvironment of patients with advanced sarcomas, presented at the 48th European Society for Medical Oncology Congress.
- 04 May 2021 Planned End Date changed from 1 Aug 2020 to 1 Aug 2021.
- 04 May 2021 Planned primary completion date changed from 1 Feb 2020 to 1 Jun 2021.